These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24810250)

  • 21. Yawning as a dose-dependent side effect of treatment with escitalopram.
    Roncero C; Mezzatesta-Gava M; Grau-López L; Daigre C
    Neurologia; 2013; 28(9):589-90. PubMed ID: 22795392
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
    Rabinowitz I; Baruch Y; Barak Y
    Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.
    Harika-Germaneau G; Langbour N; Patri S; Solinas M; Chatard A; Millet B; Hashemian F; Pérault-Pochat MC; Jaafari N; Lafay-Chebassier C
    CNS Spectr; 2022 Oct; 27(5):645-651. PubMed ID: 34313207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escitalopram prevents relapse of obsessive-compulsive disorder.
    Fineberg NA; Tonnoir B; Lemming O; Stein DJ
    Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-Dependent Escitalopram-Associated Ventricular Bigeminy.
    Naguy A; Al-Humoud AM; AlAwadhi DS; Khraibut B
    Am J Ther; 2020; 27(3):e307-e309. PubMed ID: 31567151
    [No Abstract]   [Full Text] [Related]  

  • 29. Obsessive-compulsive disorder presenting with musical obsessions in otosclerosis: a case report.
    Islam L; Scarone S; Gambini O
    J Med Case Rep; 2014 Nov; 8():384. PubMed ID: 25418908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
    Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
    Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
    Stein DJ; Carey PD; Lochner C; Seedat S; Fineberg N; Andersen EW
    CNS Spectr; 2008 Jun; 13(6):492-8. PubMed ID: 18567973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
    Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F
    Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features in two cases with musical obsessions who successfully responded to clomipramine.
    Matsui T; Matsunaga H; Ohya K; Iwasaki Y; Koshimune K; Miyata A; Kiriike N
    Psychiatry Clin Neurosci; 2003 Feb; 57(1):47-51. PubMed ID: 12519454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Stuck Song Syndrome: A Case of Musical Obsessions.
    Orjuela Rojas JM; Lizarazo Rodríguez IL
    Am J Case Rep; 2018 Nov; 19():1329-1333. PubMed ID: 30401794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of 85 patients with obsessive-compulsive disorder.
    Orloff LM; Battle MA; Baer L; Ivanjack L; Pettit AR; Buttolph ML; Jenike MA
    Am J Psychiatry; 1994 Mar; 151(3):441-2. PubMed ID: 8109659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual and auditory hallucinations associated with citalopram treatment.
    Waltereit R; Eifler S; Schirmbeck F; Zink M
    J Clin Psychopharmacol; 2013 Aug; 33(4):583-4. PubMed ID: 23775056
    [No Abstract]   [Full Text] [Related]  

  • 40. New pharmacotherapeutic approaches to obsessive-compulsive disorder.
    Figee M; Denys D
    CNS Spectr; 2009 Feb; 14(2 Suppl 3):13-23. PubMed ID: 19238126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.